- Home
- BIOX vs HLVX Comparison
BIOX vs HLVX Comparison
Compare BIOX & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIOX
- HLVX
- Stock Information
- Founded
- BIOX 2001
- HLVX 2020
- Country
- BIOX Argentina
- HLVX United States
- Employees
- BIOX N/A
- HLVX N/A
- Industry
- BIOX Agricultural Chemicals
- HLVX Biotechnology: Pharmaceutical Preparations
- Sector
- BIOX Industrials
- HLVX Health Care
- Exchange
- BIOX Nasdaq
- HLVX Nasdaq
- Market Cap
- BIOX 124.2M
- HLVX 104.3M
- IPO Year
- BIOX N/A
- HLVX 2022
- Fundamental
- Price
- BIOX $1.81
- HLVX $2.09
- Analyst Decision
- BIOX Buy
- HLVX Hold
- Analyst Count
- BIOX 3
- HLVX 1
- Target Price
- BIOX $4.50
- HLVX $2.00
- AVG Volume (30 Days)
- BIOX 585.9K
- HLVX 930.2K
- Earning Date
- BIOX 09-09-2025
- HLVX 11-06-2025
- Dividend Yield
- BIOX N/A
- HLVX N/A
- EPS Growth
- BIOX N/A
- HLVX N/A
- EPS
- BIOX N/A
- HLVX N/A
- Revenue
- BIOX $333,300,000.00
- HLVX N/A
- Revenue This Year
- BIOX $22.27
- HLVX N/A
- Revenue Next Year
- BIOX $17.09
- HLVX N/A
- P/E Ratio
- BIOX N/A
- HLVX N/A
- Revenue Growth
- BIOX N/A
- HLVX N/A
- 52 Week Low
- BIOX $1.83
- HLVX $1.34
- 52 Week High
- BIOX $8.79
- HLVX $2.17
- Technical
- Relative Strength Index (RSI)
- BIOX 20.22
- HLVX 51.28
- Support Level
- BIOX $1.97
- HLVX $2.07
- Resistance Level
- BIOX $2.94
- HLVX $2.11
- Average True Range (ATR)
- BIOX 0.20
- HLVX 0.02
- MACD
- BIOX -0.05
- HLVX -0.00
- Stochastic Oscillator
- BIOX 0.87
- HLVX 50.00
About BIOX Bioceres Crop Solutions Corp.
Bioceres Crop Solutions Corp is a fully integrated provider of crop productivity solutions, including seeds, seed traits, seed treatments, biologicals, high-value adjuvants, and fertilizers. The company has developed a multi-discipline and multi-product platform capable of providing solutions throughout the entire crop cycle, from pre-planting to transportation and storage. Some of the products offered by the company include fertilizers, inoculants, adjuvants, crop protection solutions, and seeds among others. Its operating segments are crop protection, which derives key revenue, seed and integrated products, and crop nutrition. Geographically, the majority of the company's revenue is generated from Argentina and the rest from Brazil, North America, Latin America, and other regions.
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.